POXEL Announces Successful Results For Imeglimin Phase 1 Study In Japanese Subjects And Appoints Dr. Yohjiro Itoh To Lead Its Regulatory And Clinical Operations In Asia

LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext:POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, today announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate that has already completed phase 2 clinical trials in type 2 diabetes patients in the US and EU. In addition, the Company announced that Dr. Yohjiro Itoh has joined Poxel as Vice President Regulatory and Clinical Development Asia, effective April 7th, 2015 to lead the company's drug development and registration efforts in Asia. Both events are critical steps in the Company's strategic focus on the Japanese market for the further development of Imeglimin.

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.